Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

How to treat men with advanced castration resistant prostate cancer with AR directed therapy

In advanced prostate cancer, when patients become resistant to first-line classical androgen deprivation therapy, alternative options, besides chemotherapy, do exist.
Abiraterone and Enzalutamide are recently developed hormonal treatments which have demonstrated benefit in survival.

Ian Tannock explains how to use these drugs and when chemotherapy should be recommended in castration-resistant prostate cancer patients.

References

Attard et al, J Clin Oncol 2008;26:4563-71. Reprinted with permission. © 2008. American Society of Clinical Oncology.  All rights reserved.

Tran et al: Science 2010;324:787-90. Reprinted with permission. © 2010, American Association for the Advancement of Science.  All rights reserved.

Antonarakis et al: N Engl J Med 2014;371:1028-38. Reprinted with permission. Copyright © 2014, Massachusetts Medical Society.  All rights reserved.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings